Compare CPB & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | BLTE |
|---|---|---|
| Founded | 1869 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 1994 | 2021 |
| Metric | CPB | BLTE |
|---|---|---|
| Price | $21.30 | $169.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 7 |
| Target Price | $26.06 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 7.7M | 175.7K |
| Earning Date | 06-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | ★ 6.35 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $10,253,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.11 | $492.11 |
| P/E Ratio | $13.66 | ★ N/A |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $19.56 | $68.21 |
| 52 Week High | $34.18 | $200.00 |
| Indicator | CPB | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 52.79 |
| Support Level | $21.35 | $167.80 |
| Resistance Level | $23.45 | $172.02 |
| Average True Range (ATR) | 0.66 | 8.32 |
| MACD | -0.15 | -0.10 |
| Stochastic Oscillator | 29.35 | 43.49 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.